One of the keys for successfully developing drugs against the broad spectrum of cancer cell types is structural diversity. In the current study, we focused on a family of isosteviol derivatives as potential novel antitumor agents. Isosteviol is a tetracyclic diterpenoid obtained by acid hydrolysis of steviol glycoside extracts isolated from abundant Stevia rebaudiana plants. In this work, we have designed and synthesized a panel of isosteviol triazole conjugates using “click” chemistry methodology. Evaluation of these compounds against a series of cancer cell lines derived from primary and metastatic tumors demonstrated that these conjugates exhibit cytotoxic activities with IC50 in the low μM range. In addition, their anti-proliferative activities are cancer cell type specific. Taken together, our studies underscore the importance of structural diversity in achieving cancer cell type specific drug development.
成功开发针对广谱癌细胞类型的药物的关键之一是结构多样性。在当前的研究中,我们关注了一类作为潜在新型
抗肿瘤药物的异斯特维奥衍
生物。异斯特维奥是一种由从丰富的甜叶菊植物中提取的斯特维奥苷经过酸
水解获得的四环二萜。我们在这项工作中设计并合成了一系列异斯特维奥三唑结合物,采用“点击”
化学方法。这些化合物在针对来自原发性和转移性肿瘤的多种癌
细胞系的评估中显示出细胞毒活性,其IC50值在低μM范围内。此外,它们的抗增殖活性具有癌细胞类型特异性。综上所述,我们的研究强调了结构多样性在实现针对癌细胞类型特异性药物开发中的重要性。